Central Nervous System

Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy

Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....

Synucleopathies and preclinical Parkinson disease models

Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies, have all something in common. They all belong to a group of neurodegenerative diseases called synucleinopathies, including preclinical Parkinson, characterized by the abnormal accumulation of aggregates of α-synuclein protein in neurons, nerve fibres or glial...

Neuroprotective effects of Omega-3 on 6 OHDA Parkinson preclinical mice.

Researchers from the CHU Research centre in Quebec have shown that diet can play a neuroprotective role in a preclinical Parkinson mouse model. They investigated the effects of a omega-3 polyunsaturated fatty acids-enriched diet, in the form of docosahexaenoic acid (DHA), on damaged neurons. C57BL/6...

Syncrosome Poster 6 OHDA Parkinson and dyskinesia

This poster has been presented at the last 2015 World Parkinson Congress in France, and shows interesting results concerning an antidyskinetic compound in a rat 6 OHDA Parkinson model. Dyskinesias are induced by LDopa, and various parameters are assessed, biochemical and symptomatic. Microdialysis is used to evaluate...

Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy

Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease (synuclein Parkinson), multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is...

Neurorescue and DHA on a 6OHDA preclinical Parkinson model

Preclinical data collected in models of preclinical Parkinson disease (PD) support the neuroprotective potential of omega-3 polyunsaturated fatty acids (n-3 PUFA)-enriched diet on the dopaminergic (DAergic) system. In this study, we investigated the effects of a n-3 PUFA rich diet using a neurorescue/neurorestorative paradigm....

Alpha-synuclein in Parkinson disease

Alpha Synuclein Parkinson: Formation and accumulation of misfolded protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein alpha-synuclein (α-syn) is the culprit. In the past few years, another piece of the puzzle has been added with data suggesting...